Chronic Lymphocytic Leukemia

Combination therapies utilizing ofatumumab could improve outcomes for patients with chronic lymphocytic leukemia, according to an analysis published in the Annals of Hematology.

Cyrus M. Khan, MD, discusses the issues with PI3K inhibitor trials in patients with chronic lymphocytic leukemia and the potential role of these drugs.

Lisaftoclax is a novel, orally administered small-molecule BCL-2 selective inhibitor. A study of the agent in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma will commence in the second half of 2023.

In an interview with Targeted Oncology, Cyrus M. Khan, MD reviewed the recent FDA approvals is the chronic lymphocytic leukemia space. He also discusses other FDA decisions that have recently altered the landscape for the better.

Comprehensive insight to cardiovascular safety data with available therapies and how current understandings may impact the management of patients with relapsed/refractory chronic lymphocytic leukemia.

Centering conversation on patients with relapsed/refractory chronic lymphocytic leukemia, Andrew Lipsky, MD, reviews efficacy data and considers how it impacts treatment selection.

Shared insight on ELEVATE-RR, which utilized acalabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Expert perspectives on the ALPINE trial of zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Andrew Lipsky, MD, considers the role of BTK inhibitors as second-line therapy in patients with relapsed/refractory chronic lymphocytic leukemia.

Cyrus M. Khan, discusses the current use of PI3K inhibitors to treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and how recent ODAC decisions impacted their use.

Jennifer R. Brown, MD, PhD, highlights the results from the phase 3 ALPINE study evaluating the treatment with zanubrutinib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Focused discussion on the first-line treatment armamentarium available to patients diagnosed with chronic lymphocytic leukemia.

Expert Andrew Lipsky, MD, reviews a patient case of relapsed/refractory chronic lymphocytic leukemia managed with BTK inhibition in the second-line setting.

Danielle M. Brander, MD, discusses updated results from the ELEVATE-TN trial of acalabrutinib in patients with chronic lymphocytic leukemia.

A watch-and-wait approach should remain the standard of care, even in the era of targeted therapies, in patients with early-stage chronic lymphocytic leukemia with inactive disease, according to data from the 2023 EHA Congress.

Patients aged 80 years or older and/or considered frail who received acalabrutinib for chronic lymphocytic leukemia experienced toxicities consistent with prior trials.

Results presented in a poster at the 2023 ASCO Annual Meeting demonstrated similar progression-free survival between acalabrutinib and zanubrutinib in patients with chronic lymphocytic leukemia.

Treatment with lisocabtagene maraleucel elicited encouraging responses and met the primary end point of the TRANSCEND CLL 004 trial in patients with relapsed/refractory CLL/SLL.

Susan M. O’Brien, MD, discusses the long-term results of the ELEVATE TN trial in patients with previously untreated chronic lymphocytic leukemia.

Adult patients with chronic lymphocytic leukemia had significantly better minimal residual disease and progression-free survival results when treated with venetoclax and obinutuzumab or venetoclax, obinutuzumab, and ibrutinib vs standard chemoimmunotherapy

Cyrus M. Khan, MD, discusses the most recent findings that show the efficacy of zanubrutinib for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Real-world evidence support the use of venetoclax-based regimens for patients with chronic lymphocytic leukemia based the consistent efficacy shown between the real-world and clinical trial data.

Catherine C. Coombs, MD, discusses unmet needs and offers advice for community oncologists treating patients with relapsed/refractory chronic lymphocytic leukemia.

An overview of recent data from ongoing trials evaluating CAR T-cell therapy and BTK inhibitors in patients with relapsed/refractory CLL.

An expert oncologist reviews the MURANO trial of venetoclax plus rituximab in patients with relapsed/refractory CLL and discusses MRD as a parameter of treatment response.

Catherine C. Coombs, MD, reviews currently available treatment options for patients with relapsed/refractory chronic lymphocytic leukemia.

An expert on chronic lymphocytic leukemia discusses disease progression and prognostic factors that influence treatment decisions.

Catherine C. Coombs, MD, presents the case of a 70-year-old man with relapsed/refractory chronic lymphocytic leukemia and offers her initial impressions.

John Allan, MD, provides insights on novel agents and treatment strategies currently being studied in chronic lymphocytic leukemia.

An expert hematologist-oncologist offers advice for community oncologists who are treating patients with newly diagnosed chronic lymphocytic leukemia.